Ann: Clinical milestones for 2024 & 2023 successes highlighted, page-14

A little bit volume came in this arvo. Don't think any leaks, more a realisation of how undervalued CHM currently is. Time line for 2024 has just been announced, most action will be by end of 2024. But if there was a leak then maybe a CHM 1101 deal, the ph1 results are just fantastic and as Shellbell pointed out, can compete with the other CoH trial results.

Anyway, still patience required but there is always a chance for an unexpected announcement. JC pointed again and again at the fact that CHM is now becoming interesting for big pharma. An USD100m / AUD 150m deal would be worth a sp of 20c. For the bigger forces that would be just pocket money but it would promote CHM into the next higher league. She is known very well in the CAR-T space, she helped to develop CD19 CAR-T, now developing CLTX and CD17 CAR-Ts. The ASX is currently valuing her work as NOTHING, but the US / Canadian players know her value and expertise.

GLTA